Table 1.

Summary of RCT’s on the efficacy and safety of Finerenone in patients with CKD and T2DM.

Study (Year)	Design	Intervention	Control	Main Outcomes	Effect Size
ARTS-DN (2015) [21]	RCT	Finerenone 1.25–20 mg once daily	Placebo	UACR over 90 days	There were reductions in UACR across all doses of Finerenone
FIDELIO-DKD (2020) [22]	RCT	Finerenone 10 or 20 mg once daily	Placebo	Kidney composite	Finerenone reduced the risk of CKD progression by 18%
FIGARO-DKD (2021) [23]	RCT	Finerenone 10 or 20 mg once daily	Placebo	Cardiovascular composite	Finerenone reduced the risk of composite CV events by 13%
The FIDELITY analysis (2022) [24]	Pooled analysis of FIDELIO-DKD and FIGARO-DKD	Finerenone 10 or 20 mg once daily	Finerenone + SGLT2i	Cardiovascular composite and kidney composite	Finerenone without an SGLT2i was equally as effective in reducing cardiorenal outcomes as Finerenone with SGLT2i

RCT = randomized controlled trial; SGLT2i = sodium–glucose transport protein 2 inhibitor; UACR = urine albumin–creatinine ratio; CKD = chronic kidney disease; CV = cardiovascular.